<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The known cytoprotective properties of <z:chebi fb="0" ids="32599">MgSO4</z:chebi> led the authors to study its effects on <z:mpath ids='MPATH_124'>infarct</z:mpath> size in rats when administered intraarterially before reversible focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Following an intracarotid infusion of <z:chebi fb="0" ids="32599">MgSO4</z:chebi> in the amount of 30 mg/kg (24 animals), 90 mg/kg (18 animals), or an equal volume of vehicle (23 animals), middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> was produced in rats by means of an intraluminal suture technique </plain></SENT>
<SENT sid="2" pm="."><plain>Reperfusion occurred after 1.5 (42 animals) or 2 hours (23 animals) of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Automated, volumetric measurements of 2',3',5'-triphenyl-2H-tetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi>-stained coronal brain sections demonstrated a statistically significant decrease in <z:mpath ids='MPATH_124'>infarct</z:mpath> size for <z:chebi fb="0" ids="32599">MgSO4</z:chebi> treatment groups compared to controls </plain></SENT>
<SENT sid="4" pm="."><plain>Cytoprotection was greater in animals subjected to 1.5 hours of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (28.4% reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, p &lt; 0.001, Student's t-test), than in those having 2 hours of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (19.3% reduction, p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Animals given 90 mg/kg <z:chebi fb="0" ids="32599">MgSO4</z:chebi> prior to 1.5 hours of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (12 animals) showed a 59.8% reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume compared to controls (11 animals, p &lt; 0.001) and a 43.1% reduction compared to the 30 mg/kg group (11 animals, p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of variance demonstrated the statistically significant effects of <z:chebi fb="0" ids="32599">MgSO4</z:chebi> doses on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume across <z:hpo ids='HP_0000001'>all</z:hpo> groups (F = 22.95, p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>The neuroprotective effect of intraarterial <z:chebi fb="0" ids="32599">MgSO4</z:chebi> in this model is robust, dose dependent, and related to the duration of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The compound may be valuable for limiting infarction if given intraarterially before induction of reversible <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> during cerebrovascular surgery </plain></SENT>
</text></document>